# Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Study · id `cardio:ct-nct01107886` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01107886](<https://clinicaltrials.gov/study/NCT01107886>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01107886

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 18206 participants.

## Technical summary

Registry record NCT01107886. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2014-06-13.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 18206 participants (enrolled count; ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Start date: 2010-05 (registry gives no type) (ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Results first posted: 2014-06-13 (ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Brazil; Canada; Chile; China; Czechia; France; Germany; Hong Kong SAR China; Hungary; India; Israel; Italy; Mexico; Netherlands; Peru; Poland; Puerto Rico; Russia; South Africa; Spain; Sweden; Taiwan; Thailand; United Kingdom (ClinicalTrials.gov record NCT01107886, source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01107886-2014-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
- Acronym: SAVOR- TIMI 53
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Saxagliptin
- Intervention (Drug): Placebo
- Lead sponsor: AstraZeneca
- Lead sponsor class: INDUSTRY
- Collaborator: Bristol-Myers Squibb
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: AstraZeneca (`cardio:astrazeneca`)
- Registry lists this organization as a collaborator: Bristol-Myers Squibb (`cardio:org-bristol-myers-squibb`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus (`cardio:pubmed-23992601`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial (`cardio:pubmed-25189213`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial (`cardio:pubmed-25552421`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial (`cardio:pubmed-25758769`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial (`cardio:pubmed-26358285`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c (`cardio:pubmed-26524706`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial (`cardio:pubmed-27797925`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial (`cardio:pubmed-29214305`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: c40846c4fd70940b6d670371539ed23d99794cdc68beda62f1a168f52dd40ad9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
